Precision BioSciences, Inc. (DTIL) Stock

Precision BioSciences, Inc. (DTIL) is a Healthcare stock trading at $8.85 (as of 2026-08-21), with a market capitalization of $244.27M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Precision BioSciences, Inc. develops in vivo gene editing and ex vivo allogeneic CAR T immunotherapies, including a genome-editing platform and multiple investigational CAR T candidates. Its pipeline includes programs such as PBCAR0191 and PBCAR19B for hematologic malignancies and PBCAR269A for multiple myeloma, with development activities conducted under collaboration agreements with other entities.

Understand Precision BioSciences, Inc.: how it makes money

Precision BioSciences develops clinical stage gene editing therapies, including its ARCUS genome editing platform and ex vivo allogeneic CAR T programs such as PBCAR0191 and PBCAR19B.

Because the company is clinical stage, its path to value hinges on trial progress and whether biological response signals are durable in its programs (as reflected in program specific biomarkers and patient dosing metrics).

Business quality (Weak): Strengths include an in-house genome editing platform and multiple clinical programs spanning both CAR T and other gene editing approaches. Key watch-outs are the absence of reported revenue and the large operating loss, meaning execution and clinical outcomes are critical to the future outlook.

Bull case

  • Multiple clinical programs across modalities: It develops in vivo gene editing and ex vivo allogeneic CAR T therapies, including ARCUS, PBCAR0191 (Phase 1/2a), and PBCAR19B.
  • Documented trial activity in PBGENE-HBV (ELIMINATE-B): The company reports dosing and participant counts for PBGENE-HBV, including 38 administrations and 16 patients treated.

Bear case

  • No reported revenue and large operating loss: For the period ending 2026-03-31, revenue is shown as 0.0B and operating margin is -83.7 (indicating substantial operating losses).
  • Clinical uncertainty remains central to the business model: The provided facts describe Phase 1/2a and other early clinical activity, so outcomes, durability, and next development steps are not yet established.
Valuation — source: SEC EDGAR (first-party)
Price$8.85
Market Cap$244.27M
Price / Book5.39
Price / Sales11.26
FCF Yield-42.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$34.26M
Net Margin-133.4%
Revenue Growth (YoY)-50.1%
EPS Growth (YoY)-439.0%
FCF Growth (YoY)12.3%
Financial Health — source: SEC EDGAR
Altman Z-Score-2.72 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderOctagon Capital Advisors LP ($12.30M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMichael Amoroso
Employees108
CountryUS
IPO Date2019-03-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Alector, Inc. (ALEC)
  • Acumen Pharmaceuticals, Inc. (ABOS)
  • Coherus Oncology, Inc. (CHRS)
  • Protara Therapeutics, Inc. (TARA)
  • Voyager Therapeutics, Inc. (VYGR)
  • Protalix BioTherapeutics, Inc. (PLX)
  • Armata Pharmaceuticals, Inc. (ARMP)
  • Caribou Biosciences, Inc. (CRBU)
DTIL earnings history · DTIL institutional & insider holders · DTIL KPIs & operating metrics · DTIL financials · DTIL investor presentations & press releases · DTIL SEC filings · DTIL peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.